Turbovas Tablets (Rosuvastatin)

• Composition :
  Each tablet contains 5mg/10mg/20mg/40mg of Rosuvastatin.
• Indications :
  As an adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia and to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels.
• Pharmacodynamics :
  Rosuvastatin is an inhibitor of HMG-CoA reductase, an enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.
• Dosage and administration :
  Dose range: 5-40 mg once daily. Use 40 mg dose only for patients not reaching LDL-C goal with 20 mg.
• Contraindications :
  Hypersensitivity to the active substance(s) or to any of the excipients. Active liver disease, which may include unexplained persistent elevations in hepatictransaminase levels, pregnant and nursing women.
• Precautions and warnings :
  Skeletal muscle effects (e.g., myopathy and rhabdomyolysis). Monitor liver enzymes before and during treatment. Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including Rosuvastatin, Immune-Mediated Necrotizing Myopathy
• Use in pregnancy, lactation & pediatrics :
  Pregnancy Category X. Rosuvastatin is contraindicated in women who are or may become pregnant. Lactating women should be advised not to nurse their infants. Should be avoided in children below 6 years.
• Drug interactions :
  Following drug interact with Rosuvastatin caution to be taken with Cyclosporine, Gemfibrozil, Lopinavir/Ritonavir or atazanavir/ritonavir, Coumarin anticoagulants and fibrates. Aspirin administered with anticoagulant and anti-platelets causes increased risk of bleeding.
• Adverse reactions :
  The most commonly reported adverse events are headache, myalgia, abdominal pain, asthenia, and nausea.
• Therapy Area :
  Lipid Lowering agents